Develops drugs for blood cancer and hepatitis.
Jun 2026Revenue $0.00/yrExpenses $7.34M/yr
No trend
Figures by year
When will Exicure be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $0.00 and expenses $7.34M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $0.00 | $4.23M | −$4.23M |
| Dec 2024 | $500K | $12.7M | −$12.2M |
| Dec 2023 | $0.00 | $15.0M | −$15.0M |
| Dec 2022 | $28.8M | $30.7M | −$1.83M |
| Dec 2021 | −$483K | $62.1M | −$62.5M |
| Dec 2020 | $16.6M | $42.0M | −$25.4M |
| Dec 2019 | $1.30M | $27.9M | −$26.6M |
| Dec 2018 | $118K | $21.9M | −$21.8M |
| Dec 2017 | $9.72M | $20.1M | −$10.4M |
| Dec 2016 | $1.04M | $17.2M | −$16.2M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.